Atenolol for Osteoporosis Prevention

(APO Trial)

Recruiting in Palo Alto (17 mi)

+2 other locations

Overseen by Sundeep Khosla, MD

Age: 18+

Sex: Female

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Sundeep Khosla, M.D.

Prior Safety Data

Trial Summary

What is the purpose of this trial?

Evaluate whether treatment with a widely used beta blocker, atenolol, will prevent bone loss at the lower back and hip in postmenopausal women.

Research Team

Sundeep Khosla, MD

Principal Investigator

Mayo Clinic

Eligibility Criteria

This trial is for postmenopausal women aged 50-75 who are healthy and can consent to participate. They must not have severe chronic diseases, recent use of certain heart or bone medications, a history of osteoporotic fractures, or very low blood pressure/heart rate.

Inclusion Criteria

I am between 50 and 75 years old.

Able and willing to provide informed consent

I am a postmenopausal woman.

Exclusion Criteria

A1c- ≥8

CBC- Per PI interpretation of each patient

I have a significant health condition like severe liver, kidney disease, or cancer.

Treatment Details

Interventions

• Atenolol (Beta Blocker)
• Placebo (Other)

Trial Overview The APO trial is testing if atenolol, a common beta blocker medication, can prevent bone loss in the lower back and hip among postmenopausal women. Participants will either receive atenolol or a placebo (a pill with no active drug).

Participant Groups

Group I: Atenolol Experimental Treatment 1 Intervention

Study subjects will take Atenolol 50 mg daily over 2 years

Group II: Placebo Placebo Group 1 Intervention

Study subjects will take a placebo daily over 2 years

Who Is Running the Clinical Trial?

Sundeep Khosla, M.D.

Lead Sponsor

Trials

2

Recruited

490+

Columbia University

Collaborator

Trials

1,529

Recruited

2,832,000+

Dr. Katrina Armstrong

Columbia University

Chief Executive Officer

MD from Johns Hopkins University, MS in Epidemiology from Harvard School of Public Health

Dr. Katrina Armstrong

Columbia University

Chief Medical Officer

MD from Harvard Medical School

MaineHealth

Collaborator

Trials

76

Recruited

43,800+

Dr. Andrew Mueller

MaineHealth

Chief Executive Officer since 2021

MD from University of North Carolina School of Medicine

Dr. Adrian Moran

MaineHealth

Chief Medical and Transformation Officer

MD from University College Dublin, Executive MBA in Healthcare from Brandeis University

University of California, San Francisco

Collaborator

Trials

2,636

Recruited

19,080,000+

Suresh Gunasekaran

University of California, San Francisco

Chief Executive Officer since 2022

MBA from Southern Methodist University

Dr. Lukejohn Day

University of California, San Francisco

Chief Medical Officer

MD from Stanford University School of Medicine